According to foreign media reports, genetic testing company Invitae has filed for bankruptcy protection with the District Court of New Jersey. This once-star biotech company, valued at up to 55 billion yuan, has collapsed. Invitae's bankruptcy filing means that another investment by SoftBank Vision Fund has gone down the drain in 2024, and Masayoshi Son's capital landscape has been hit hard again. According to a report by The Wall Street Journal, in 2021, Invitae received a $1.15 billion (about 8.3 billion yuan) investment from SoftBank, led by Masayoshi Son, from Vision Fund.